Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

idasanutlin (RG7388)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

MDM2 inhibitor

Related drugs:

TP53 wild-type	Acute Myelogenous Leukemia	TP53 wild-type	Acute Myelogenous Leukemia	RG7388 Resistant: B - Late Trials RG7388 Resistant : B	RG7388 Resistant: B - Late Trials RG7388 Resistant : B
BCL2/MCL1 ratio elevation	Acute Myelogenous Leukemia	BCL2/MCL1 ratio elevation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
BCL2/BCL2L1 ratio elevation	Acute Myelogenous Leukemia	BCL2/BCL2L1 ratio elevation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
PTPN11 mutations + MCL1 overexpression	Acute Myelogenous Leukemia	PTPN11 mutations + MCL1 overexpression	Acute Myelogenous Leukemia	RG7388 Sensitive: C3 – Early Trials RG7388 Sensitive : C3	RG7388 Sensitive: C3 – Early Trials RG7388 Sensitive : C3
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	RG7388 Resistant: C3 – Early Trials RG7388 Resistant : C3	RG7388 Resistant: C3 – Early Trials RG7388 Resistant : C3
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	RG7388 Resistant: C3 – Early Trials RG7388 Resistant : C3	RG7388 Resistant: C3 – Early Trials RG7388 Resistant : C3
MDM2 overexpression	Liposarcoma	MDM2 overexpression	Liposarcoma	erdafitinib + RG7388 Sensitive: D – Preclinical erdafitinib + RG7388 Sensitive : D	erdafitinib + RG7388 Sensitive: D – Preclinical erdafitinib + RG7388 Sensitive : D